Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:17726540  

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.

Lucia Regales | Marissa N Balak | Yixuan Gong | Katerina Politi | Ayana Sawai | Carl Le | Jason A Koutcher | David B Solit | Neal Rosen | Maureen F Zakowski | William Pao
PloS one | 2007

The EGFR T790M mutation confers acquired resistance to kinase inhibitors in human EGFR mutant lung adenocarcinoma, is occasionally detected before treatment, and may confer genetic susceptibility to lung cancer.

Pubmed ID: 17726540

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: K08 CA097980
  • Agency: NCI NIH HHS, United States
    Id: P30 CA08748
  • Agency: NCI NIH HHS, United States
    Id: P30 CA008748
  • Agency: NCI NIH HHS, United States
    Id: R01 CA121210
  • Agency: NCI NIH HHS, United States
    Id: R01 CA120247
  • Agency: NCI NIH HHS, United States
    Id: R24CA83084
  • Agency: NCI NIH HHS, United States
    Id: R24 CA083084

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Genentech (tool)

RRID:SCR_003997

A biotechnology corporation that uses human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions.

View all literature mentions